Transaction DateRecipientSharesTypePriceValue
17th March 2020John W. Higuchi220,000Open or private purchase$0.32$69,542.00
31st December 2019Mahesh V. Patel40,000Open or private purchase$0.38$15,340.00
10th December 2019Mahesh V. Patel25,000Open or private purchase$0.40$9,975.00
4th December 2019Mahesh V. Patel145,000Exercise of derivative$0.00
4th December 2019Morgan R Brown17,250Open or private sale$0.41$7,075.95
4th December 2019Mahesh V. Patel43,500Open or private sale$0.41$17,835.00
4th December 2019Morgan R Brown57,500Exercise of derivative$0.00
26th November 2019Mahesh V. Patel1,100Open or private purchase$0.43$469.70
26th November 2019Mahesh V. Patel21,928Open or private purchase$0.43$9,385.18
26th November 2019Mahesh V. Patel1,272Open or private purchase$0.43$542.51
Lipocine logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.

Lipocine, Inc. focuses on the oral testosterone replacement therapy and preterm birth prevention. The company was founded in 2011 and is headquartered in Salt Lake City, UT.

Ticker: LPCN
Sector: Health Technology
Industry: Pharmaceuticals: Other
SEC Central Index Key (CIK): 1535955
Employees: 12
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags